Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MIRA Pharmaceuticals, Inc. - Common Stock (NQ:MIRA)

1.647 +0.036 (+2.27%)
Streaming Delayed Price Updated: 10:08 AM EST, Dec 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MIRA Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication
Via ACCESS Newswire
News headline image
In today's session, these stocks are experiencing unusual volume. ↗
In today's session, these stocks are experiencing unusual volume. 
Via Chartmill
News headline image
Mag 7 Undercard Stocks: PRSO, MIRA, WHWK, RDZN Surge on AI, Biotech, and Technology News – Full List Inside
Via AB Newswire
Topics Artificial Intelligence Intellectual Property
Mira Pharmaceuticals Stock Soars 70% After-Hours As Pain Drug Outperforms Morphine; Retail Sees ‘Blockbuster Drug’ In The Making ↗
Via Stocktwits
News headline image
Which stocks are experiencing notable movement on Thursday? ↗
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
MIRA Pharmaceuticals Stock Surges Following Positive Preclinical Data ↗
MIRA Pharmaceuticals shares are trading significantly higher on Thursday following the announcement of new preclinical data for its lead candidate Mira-55. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Dow Dips Over 100 Points; US Crude Oil Inventories Surge ↗
 
Via Benzinga
Topics Stocks
News headline image
Top movers analysis in the middle of the day on 2025-10-16: top gainers and losers in today's session. ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
Thursday's session: gap up and gap down stocks ↗
Let's have a look at what is happening on the US markets on Thursday. Below you can find the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Dow Surges Over 100 Points; Charles Schwab Posts Upbeat Earnings ↗
 
Via Benzinga
Topics Stocks
News headline image
Stay updated with the stocks that are on the move in today's pre-market session. ↗
The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
MIRA Pharmaceuticals Announces Oral Mira-55 Outperformed Injected Morphine in Normalizing Pain and Reducing Inflammation, Supporting Its Planned IND for Chronic Inflammatory Pain
Via ACCESS Newswire
News headline image
Why J.B. Hunt Transport Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Why Mira Pharmaceuticals Shares Rose 69% After Hours? ↗
Mira Pharmaceuticals shares surged 68.94% in after-hours trading after the company reported promising preclinical results for its pain treatment candidate, Mira-55. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Wednesday's after hours session: top gainers and losers ↗
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
News headline image
MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine Addiction
Via ACCESS Newswire
News headline image
MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog
Via ACCESS Newswire
News headline image
MIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals
Via ACCESS Newswire
News headline image
Monday's after hours session: top gainers and losers ↗
The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
MIRA Pharmaceuticals Shareholders Approve Acquisition of SKNY Pharmaceuticals, Advancing Next-Generation Oral Therapeutic for Obesity and Smoking Cessation
Via ACCESS Newswire
News headline image
MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage
Via ACCESS Newswire
News headline image
MIRA Pharmaceuticals' Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus Ketamine, Gabapentin, or Pregabalin
Via ACCESS Newswire
News headline image
MIRA Pharmaceuticals Reports New Topical Ketamir-2 shows comparable effects to Injected Morphine in Preclinical Pain Study
Via ACCESS Newswire
News headline image
MIRA Pharmaceuticals Announces FDA Clearance of IND for Ketamir-2, Enabling U.S. Clinical Trials in Neuropathic Pain
Via ACCESS Newswire
News headline image
MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for Acquisition
Via ACCESS Newswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.